This year the Insight for MAnaging Growth for Endocrine nurses (IMAGE) conference was held on 10-11th October 2019 at the Radis […]
In our first edition, Professor Frederic Castinetti discussing the results of an international collaboration to study the natural history and treatment outcomes of multiple endocrine neoplasia type 2B, and Professor Martin Savage comments on a randomized trial of letrozole versus testosterone in boys with constitutional delay of growth and puberty.
A girl aged 15 years and 2 months is referred to the Endocrine Clinic for short stature and delayed puberty.
Managing growth disorders: integrating technology into a personalised approach
This is an on-demand webcast discussing non-adherence to GH therapy, why this is a probl […]
Researchers report sustained improvements in skeletal mineralisation, along with other benefits including improved growth and respiratory function, in children with life-threatening perinatal or infantile hypophosphatasia during 7 years of treatment with asfotase alfa.
Most children continue on a normal growth trajectory if their recombinant human growth hormone dose is reduced by half after they have achieved catch-up growth, shows a randomised trial.
Rare forms of maturity onset diabetes of the young are frequently misdiagnosed as type 1 or even type 2 diabetes, say researchers, despite patients presenting with distinct characteristics.
Tongue lesions, gastrointestinal problems and musculoskeletal complaints are the most common symptoms for which children are investigated in the years leading up to a multiple endocrine neoplasia type 2B diagnosis, say researchers.
Established genetic risk factors for adult-onset Graves’ disease apply equally in patients with a diagnosis in childhood, say researchers.
Adherence to recombinant human growth hormone has a strong influence on the growth response of children with growth hormone deficiency, especially during the second year of treatment, report researchers.